Sinotherapeutics Inc. A (688247) - Total Assets
Based on the latest financial reports, Sinotherapeutics Inc. A (688247) holds total assets worth CN¥1.45 Billion CNY (≈ $212.78 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 688247 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Sinotherapeutics Inc. A - Total Assets Trend (2020–2025)
This chart illustrates how Sinotherapeutics Inc. A's total assets have evolved over time, based on quarterly financial data. See Sinotherapeutics Inc. A shareholders equity for net asset value and shareholders' equity analysis.
Sinotherapeutics Inc. A - Asset Composition Analysis
Current Asset Composition (December 2025)
Sinotherapeutics Inc. A's total assets of CN¥1.45 Billion consist of 65.0% current assets and 35.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 28.3% |
| Accounts Receivable | CN¥79.95 Million | 5.6% |
| Inventory | CN¥72.55 Million | 5.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥14.98 Million | 1.0% |
| Goodwill | CN¥16.22 Million | 1.1% |
Asset Composition Trend (2020–2025)
This chart illustrates how Sinotherapeutics Inc. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sinotherapeutics Inc. A stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sinotherapeutics Inc. A's current assets represent 65.0% of total assets in 2025, a decrease from 73.5% in 2020.
- Cash Position: Cash and equivalents constituted 28.3% of total assets in 2025, down from 58.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 6.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 5.6% of total assets.
Sinotherapeutics Inc. A Competitors by Total Assets
Key competitors of Sinotherapeutics Inc. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
JW Pharmaceutical Corp
KO:001067
|
Korea | ₩611.56 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275
|
China | CN¥4.30 Billion |
|
Fuan Pharmaceutical Group Co
SHE:300194
|
China | CN¥5.97 Billion |
|
DRI Healthcare Trust
TO:DHT-U
|
Canada | $967.26 Million |
|
Hainan Shuangcheng Pharmaceut
SHE:002693
|
China | CN¥816.14 Million |
Sinotherapeutics Inc. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.98 | 9.73 | 11.70 |
| Quick Ratio | 10.24 | 8.72 | 11.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥868.33 Million | CN¥882.27 Million | CN¥869.63 Million |
Sinotherapeutics Inc. A - Advanced Valuation Insights
This section examines the relationship between Sinotherapeutics Inc. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.29 |
| Latest Market Cap to Assets Ratio | 0.40 |
| Asset Growth Rate (YoY) | -1.0% |
| Total Assets | CN¥1.44 Billion |
| Market Capitalization | $569.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sinotherapeutics Inc. A's assets below their book value (0.40x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Sinotherapeutics Inc. A's assets decreased by 1.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Sinotherapeutics Inc. A (2020–2025)
The table below shows the annual total assets of Sinotherapeutics Inc. A from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.44 Billion ≈ $210.44 Million |
-1.05% |
| 2024-12-31 | CN¥1.45 Billion ≈ $212.66 Million |
+6.73% |
| 2023-12-31 | CN¥1.36 Billion ≈ $199.25 Million |
+2.20% |
| 2022-12-31 | CN¥1.33 Billion ≈ $194.96 Million |
+53.88% |
| 2021-12-31 | CN¥865.81 Million ≈ $126.69 Million |
+16.51% |
| 2020-12-31 | CN¥743.14 Million ≈ $108.74 Million |
-- |
About Sinotherapeutics Inc. A
Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company's products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extende… Read more